Target Price | $4.92 |
Price | $0.78 |
Potential |
534.33%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target Nektar Therapeutics 2026 .
The average Nektar Therapeutics target price is $4.92.
This is
534.33%
register free of charge
$7.00
803.11%
register free of charge
$2.00
158.03%
register free of charge
|
|
A rating was issued by 8 analysts: 6 Analysts recommend Nektar Therapeutics to buy, 1 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Nektar Therapeutics stock has an average upside potential 2026 of
534.33%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 98.43 | 63.85 |
9.22% | 35.13% | |
EBITDA Margin | -130.78% | -202.05% |
9.06% | 54.49% | |
Net Margin | -109.47% | -191.81% |
63.38% | 75.22% |
8 Analysts have issued a sales forecast Nektar Therapeutics 2025 . The average Nektar Therapeutics sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Nektar Therapeutics 2025 . The average Nektar Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Nektar Therapeutics Analysts have issued a net profit forecast 2025. The average Nektar Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.58 | -0.66 |
60.00% | 13.79% | |
P/E | negative | |
EV/Sales | 1.31 |
8 Analysts have issued a Nektar Therapeutics forecast for earnings per share. The average Nektar Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Nektar Therapeutics...
Analyst | Rating | Action | Date |
---|---|---|---|
Jefferies |
Locked
➜
Locked
|
Locked | Apr 11 2025 |
Oppenheimer |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 25 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
B. Riley Securities |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 04 2024 |
Analyst Rating | Date |
---|---|
Locked
Jefferies:
Locked
➜
Locked
|
Apr 11 2025 |
Locked
Oppenheimer:
Locked
➜
Locked
|
Mar 14 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 13 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 25 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 13 2025 |
Locked
B. Riley Securities:
Locked
➜
Locked
|
Jan 08 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 04 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.